Jonathan Wolleben
Stock Analyst at JMP Securities
(4.09)
# 420
Out of 4,829 analysts
198
Total ratings
46%
Success rate
12.71%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $74 → $76 | $44.27 | +71.67% | 10 | May 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Reiterates: Market Outperform | $443 | $299.69 | +47.82% | 12 | Apr 24, 2025 | |
| MBX MBX Biosciences | Initiates: Market Outperform | $38 | $11.11 | +242.03% | 1 | Apr 10, 2025 | |
| ALT Altimmune | Reiterates: Market Outperform | $25 | $5.59 | +347.23% | 12 | Apr 2, 2025 | |
| CLSD Clearside Biomedical | Reiterates: Market Outperform | $5 | $0.86 | +482.21% | 10 | Mar 28, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Market Outperform | $19 | $11.90 | +59.73% | 3 | Mar 26, 2025 | |
| AURA Aura Biosciences | Maintains: Market Outperform | $21 → $19 | $5.23 | +263.29% | 7 | Mar 26, 2025 | |
| SKYE Skye Bioscience | Reiterates: Market Outperform | $15 | $1.81 | +728.73% | 2 | Mar 21, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Market Outperform | $61 | $42.95 | +42.03% | 11 | Mar 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Market Outperform | $22 → $19 | $7.06 | +169.12% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $10 | $9.83 | +1.73% | 13 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $55 | $16.60 | +231.33% | 11 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $9.97 | +80.54% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $26 | $4.23 | +514.66% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $91 → $87 | $25.57 | +240.24% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $92 → $91 | $30.68 | +196.61% | 14 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $75 | $57.38 | +30.71% | 2 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $2.86 | +214.69% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $38.97 | +28.30% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $74.57 | +20.69% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $127.04 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.61 | +398.44% | 7 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $648.25 | -25.18% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $3 | $0.33 | +814.63% | 6 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $3.26 | +881.60% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $2.12 | +1,079.25% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.29 | +2,630.38% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $27.36 | -12.28% | 1 | May 12, 2023 |
Mirum Pharmaceuticals
May 9, 2025
Maintains: Market Outperform
Price Target: $74 → $76
Current: $44.27
Upside: +71.67%
Madrigal Pharmaceuticals
Apr 24, 2025
Reiterates: Market Outperform
Price Target: $443
Current: $299.69
Upside: +47.82%
MBX Biosciences
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $11.11
Upside: +242.03%
Altimmune
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $25
Current: $5.59
Upside: +347.23%
Clearside Biomedical
Mar 28, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $0.86
Upside: +482.21%
KalVista Pharmaceuticals
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $11.90
Upside: +59.73%
Aura Biosciences
Mar 26, 2025
Maintains: Market Outperform
Price Target: $21 → $19
Current: $5.23
Upside: +263.29%
Skye Bioscience
Mar 21, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $1.81
Upside: +728.73%
Protagonist Therapeutics
Mar 10, 2025
Reiterates: Market Outperform
Price Target: $61
Current: $42.95
Upside: +42.03%
Ocular Therapeutix
Mar 4, 2025
Maintains: Market Outperform
Price Target: $22 → $19
Current: $7.06
Upside: +169.12%
Mar 4, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $9.83
Upside: +1.73%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $55
Current: $16.60
Upside: +231.33%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $9.97
Upside: +80.54%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $26
Current: $4.23
Upside: +514.66%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $91 → $87
Current: $25.57
Upside: +240.24%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $92 → $91
Current: $30.68
Upside: +196.61%
Dec 23, 2024
Reiterates: Market Outperform
Price Target: $75
Current: $57.38
Upside: +30.71%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $2.86
Upside: +214.69%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $38.97
Upside: +28.30%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $74.57
Upside: +20.69%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $127.04
Upside: -
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $1.61
Upside: +398.44%
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $648.25
Upside: -25.18%
Sep 26, 2024
Reiterates: Market Outperform
Price Target: $3
Current: $0.33
Upside: +814.63%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $3.26
Upside: +881.60%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $2.12
Upside: +1,079.25%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.29
Upside: +2,630.38%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $27.36
Upside: -12.28%